Jean-Cosme Dodart
Chief Scientific OfficerDr. Jean-Cosme Dodart, Ph. D. serves as Chief Scientific Officer at Vaxxinity, Inc. since 2024 and served as its Senior Vice President of Preclinical R&D since 2023 until May 2023 and served as its Senior Vice President of Research since May 2023 until 2024 and served as its Senior Vice President of Research since 2023 until 2023 and was its Senior Vice President of Preclinical R&D until 2023. He served as Director of Pharmacology at Sage Therapeutics, Inc since 2011. Dr. Dodart has worked for long span in drug discovery in the field of neurological and psychiatric disorders. Prior to joining SAGE Therapeutics, Dr. Dodart was Director of the NeuroBehavior Laboratory at the Brigham & Women's Hospital and assistant professor of neurology at Harvard Medical School. During his tenures at Eli Lilly & Co. and Merck & Co. he contributed to diverse neuroscience research projects at different stages of drug discovery and development and developed a variety of rodent behavioral/cognitive animal models and in vivo pharmacodynamic assays that have demonstrated strong translational value. Dr. Dodart earned a M. S. degree in cell biology and physiology from University Pierre & Marie Curie in Paris and a Ph. D. degree in neuroscience from University Louis Pasteur, Strasbourg, France.
Positions
- Company NameVaxxinity, Inc.Stock CodeVAXXPositionChief Scientific OfficerColleagues
- LGLouis Garfield ReeseCo-Founder & Executive Chairman of the Board
- MMMei Mei HuCo-Founder, President, CEO & Director
- JPJason PesileChief Accounting Officer
- MJMark JoinnidesChief of Staff
- GRGeorge Ronald HornigIndependent Director
- GBGabrielle B. ToledanoIndependent Director
- LOLandon OgilvieLead Independent Director
